Filter posts

BIO on CNBC: IPR System Weakens Medical Innovation

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on …

Here are the Facts about the IPR Kill Rate

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the …

102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation

A diverse group of more than 100 national and state-based advocacy organizations have united to …

Congress Blog: Medical Advances Keep Me Running

This week, 74-year-old multiple myeloma patient Don Wright shares his story on how cancer drugs have …

Register for the 2015 BIO IP & Diagnostics Symposium!

The Third Annual BIO IP & Diagnostics Symposium takes place on September 18, 2015 in Alexandria, …

WSJ: U.S. Concessions on TPP Means Fewer Cures

Today’s Wall Street Journal editorial, Pacific Trade Brinksmanship, does an outstanding job highlighting the important …

New Report Suggests RDP Does Not Increase Healthcare Expenditures

A new paper by the Geneva Network suggests that increasing the period of regulatory data …

225th Anniversary of First U.S. Patent

225 years ago last Friday the first U.S. patent was issued to Samuel Hopkins for …

Seventy Nine House Members Express Concern with H.R. 9

House leaders made the decision earlier this month to remove patent reform legislation from the …

CNBC Commentary: Hedge funds, 'reverse trolls' crushing biopharma innovation

Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to …